663 related articles for article (PubMed ID: 29318368)
1. Increased levels of advanced glycation end products positively correlate with iron overload and oxidative stress markers in patients with β-thalassemia major.
Mirlohi MS; Yaghooti H; Shirali S; Aminasnafi A; Olapour S
Ann Hematol; 2018 Apr; 97(4):679-684. PubMed ID: 29318368
[TBL] [Abstract][Full Text] [Related]
2. Correlation of iron overload and glomerular filtration rate estimated by cystatin C in patients with β-thalassemia major.
Al-Khabori M; Bhandari S; Al-Rasadi K; Mevada S; Al-Dhuhli H; Al-Kemyani N; Daar S
Hemoglobin; 2014; 38(5):365-8. PubMed ID: 25074643
[TBL] [Abstract][Full Text] [Related]
3. Liver iron concentrations and urinary hepcidin in beta-thalassemia.
Origa R; Galanello R; Ganz T; Giagu N; Maccioni L; Faa G; Nemeth E
Haematologica; 2007 May; 92(5):583-8. PubMed ID: 17488680
[TBL] [Abstract][Full Text] [Related]
4. Non-transferrin-bound labile plasma iron and iron overload in sickle-cell disease: a comparative study between sickle-cell disease and beta-thalassemic patients.
Koren A; Fink D; Admoni O; Tennenbaum-Rakover Y; Levin C
Eur J Haematol; 2010 Jan; 84(1):72-8. PubMed ID: 19732137
[TBL] [Abstract][Full Text] [Related]
5. N-Acetylcysteine supplementation reduces oxidative stress and DNA damage in children with β-thalassemia.
Ozdemir ZC; Koc A; Aycicek A; Kocyigit A
Hemoglobin; 2014; 38(5):359-64. PubMed ID: 25222041
[TBL] [Abstract][Full Text] [Related]
6. Oxidative stress and antioxidant status in beta-thalassemia major: iron overload and depletion of lipid-soluble antioxidants.
Livrea MA; Tesoriere L; Pintaudi AM; Calabrese A; Maggio A; Freisleben HJ; D'Arpa D; D'Anna R; Bongiorno A
Blood; 1996 Nov; 88(9):3608-14. PubMed ID: 8896430
[TBL] [Abstract][Full Text] [Related]
7. Liver fibrosis and iron levels during long-term deferiprone treatment of thalassemia major patients.
Wu SF; Peng CT; Wu KH; Tsai CH
Hemoglobin; 2006; 30(2):215-8. PubMed ID: 16798646
[TBL] [Abstract][Full Text] [Related]
8. Oral iron chelation therapy for thalassaemia: an uncertain scene.
Pippard MJ; Weatherall DJ
Br J Haematol; 2000 Oct; 111(1):2-5. PubMed ID: 11091177
[No Abstract] [Full Text] [Related]
9. Oxidative status and malondialdehyde in beta-thalassaemia patients.
Cighetti G; Duca L; Bortone L; Sala S; Nava I; Fiorelli G; Cappellini MD
Eur J Clin Invest; 2002 Mar; 32 Suppl 1():55-60. PubMed ID: 11886433
[TBL] [Abstract][Full Text] [Related]
10. Iron status and oxidative stress in beta-thalassemia patients in Jakarta.
Laksmitawati DR; Handayani S; Udyaningsih-Freisleben SK; Kurniati V; Adhiyanto C; Hidayat J; Kusnandar S; Dillon HS; Munthe BG; Wirawan R; Soegianto RR; Ramelan W; Freisleben HJ
Biofactors; 2003; 19(1-2):53-62. PubMed ID: 14757977
[TBL] [Abstract][Full Text] [Related]
11. Management of Iron Overload in Beta-Thalassemia Patients: Clinical Practice Update Based on Case Series.
Pinto VM; Forni GL
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33233561
[TBL] [Abstract][Full Text] [Related]
12. Association of iron overload and oxidative stress with insulin resistance in transfusion-dependent beta-thalassemia major and beta-thalassemia/HbE patients.
Tangvarasittichai S; Pimanprom A; Choowet A; Tangvarasittichai O
Clin Lab; 2013; 59(7-8):861-8. PubMed ID: 24133917
[TBL] [Abstract][Full Text] [Related]
13. Non-transferrin-bound iron during blood transfusion cycles in beta-thalassemia major.
Grosse R; Lund U; Caruso V; Fischer R; Janka GE; Magnano C; Engelhardt R; Dürken M; Nielsen P
Ann N Y Acad Sci; 2005; 1054():429-32. PubMed ID: 16339692
[TBL] [Abstract][Full Text] [Related]
14. Combined therapy with desferrioxamine and deferiprone in beta thalassemia major patients with transfusional iron overload.
Daar S; Pathare AV
Ann Hematol; 2006 May; 85(5):315-9. PubMed ID: 16450126
[TBL] [Abstract][Full Text] [Related]
15. The deferiprone and deferasirox combination is efficacious in iron overloaded patients with β-thalassemia major: A prospective, single center, open-label study.
Totadri S; Bansal D; Bhatia P; Attri SV; Trehan A; Marwaha RK
Pediatr Blood Cancer; 2015 Sep; 62(9):1592-6. PubMed ID: 25820920
[TBL] [Abstract][Full Text] [Related]
16. Effectiveness of deferiprone in transfusion-independent beta-thalassemia/HbE patients.
Akrawinthawong K; Chaowalit N; Chatuparisuth T; Siritanaratkul N
Hematology; 2011 Mar; 16(2):113-22. PubMed ID: 21418744
[TBL] [Abstract][Full Text] [Related]
17. Heart Rate Variability for Early Detection of Iron Overload Cardiomyopathy in β-Thalassemia Patients.
Koonrungsesomboon N; Tantiworawit A; Phrommintikul A; Saekho S; Srichairattanakool S; Chattipakorn N
Hemoglobin; 2015; 39(4):281-6. PubMed ID: 26029793
[TBL] [Abstract][Full Text] [Related]
18. Daily alternating deferasirox and deferiprone therapy for "hard-to-chelate" beta-thalassemia major patients.
Balocco M; Carrara P; Pinto V; Forni GL
Am J Hematol; 2010 Jun; 85(6):460-1. PubMed ID: 20513129
[No Abstract] [Full Text] [Related]
19. Iron chelation in thalassemia: combined or monotherapy? The Egyptian experience.
El-Beshlawy A; Manz C; Naja M; Eltagui M; Tarabishi C; Youssry I; Sobh H; Hamdy M; Sharaf I; Mostafa A; Shaker O; Hoffbrand AV; Taher A
Ann Hematol; 2008 Jul; 87(7):545-50. PubMed ID: 18351337
[TBL] [Abstract][Full Text] [Related]
20. Pathogenesis and management of iron toxicity in thalassemia.
Hershko C
Ann N Y Acad Sci; 2010 Aug; 1202():1-9. PubMed ID: 20712765
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
